SABCS - RxPONDER TRIAL Study


RxPONDER Study Results Demonstrate that the Oncotype DX®
Test Can Now Spare Chemotherapy Use in the Majority of Women
with Node-positive Early-stage Breast Cancer.

SABCS - RxPONDER TRIAL Study

RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women
with Node-positive Early-stage Breast Cancer

• First results from the independent SWOG Cancer Research Network-led Phase III
study to be presented at the 2020 San Antonio Breast Cancer Symposium
RxPONDER results from over 5,000 women likely to transform the treatment of
node-positive breast cancer, as the TAILORx study did in node-negative disease

MADISON, Wis., December 9, 2020 – Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER, trial successfully defined the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Oncotype DX Breast Recurrence Score® results of 0 to 25. First results from the study, led by the independent SWOG Cancer Research Network, and sponsoredby the National Cancer Institute (NCI), identified the majority of women with 1-3 positive nodes who received no benefit from chemotherapy.

For more information please click here

11.12.2020